Letter to Editor Recovery From Paraplegia With Administration of Erlotinib in a Patient With Lung Adenocarcinoma

Wspolczesna Onkologia - Poland
doi 10.5114/wo.2014.41393
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Termedia Sp. z.o.o.

Related search

Successful Rechallenge With Reduced Dose of Erlotinib in a Patient With Lung Adenocarcinoma Who Developed Erlotinib‑associated Leukocytoclastic Vasculitis: A Case Report

Oncology Letters
Cancer ResearchOncology
2012English

Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient With Lung Adenocarcinoma Following Treatment With Erlotinib and Osimertinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Successful Rechallenge With Gefitinib for an Initial Erlotinib-Responder With Advanced Lung Adenocarcinoma

Tuberculosis and Respiratory Diseases
PulmonaryInfectious DiseasesRespiratory Medicine
2011English

Disseminated Intravascular Coagulation in a Patient With Advanced Lung Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Nivolumab-Related Cutaneous Sarcoidosis in a Patient With Lung Adenocarcinoma

JAAD Case Reports
Dermatology
2017English

Complete Pathological Response to Crizotinib in a Patient With ALK-rearranged Lung Adenocarcinoma

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2020English

Prolonged Response to First-Line Erlotinib for Advanced Lung Adenocarcinoma

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2008English

Erlotinib Resistance With EGFR L858r/Y891d Double Mutation in a Patient With Non–Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy